Indications:
LUMAKRAS is an inhibitor of the RASGTPase family indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation (as determined by an FDA-approved test) who have received at least one prior systemic therapy.
Dosage:
The recommended dose is 960 mg, taken orally once daily, and treatment duration is until disease progression or unacceptable toxicity occurs. Swallow the tablet whole without crushing, chewing, breaking, or opening it. It can be taken with or without food.
Dose reduction for adverse reactions: The first dose reduction is 480 mg orally once a day. The second dose reduction is 240 mg orally once a day. If adverse reactions occur, a maximum of 2 dose reductions are allowed, and the drug should be discontinued if the patient cannot tolerate the lowest dose of 240 mg orally once a day.
Missed dose: If you miss a dose, use the medicine as soon as possible, but if it is more than 6 hours after taking the medicine, skip the missed dose. Do not use two doses at one time. Wait until the scheduled time to take this medicine as originally planned. Avoid repeated use of the medicine within a short period of time.
Adverse reactions:
The most common adverse reactions (≥20%) were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory abnormalities (≥25%) were lymphocytopenia, hemoglobin decrease, aspartate aminotransferase increase, alanine aminotransferase increase, calcium decrease, alkaline phosphatase increase, urine protein increase, and sodium decrease.
